Bronchitis is a respiratory disease which causes inflammation in the airways, also known as bronchi, of the lungs. It leads to irritation and inflammation of the lining of bronchial tubes that are responsible for carrying air to and from the lungs. Bronchitis is caused by bacteria and viruses. However, viral infection is most common. Shortness of breath, cough with thick mucus, chest discomfort, wheezing, fatigue, slight fever, and chills are the common symptoms of bronchitis. Bronchitis can be either acute or chronic. Acute bronchitis, also known as chest cold, is a temporary inflammation of the bronchial tubes that leads to cough and mucus production and lasts for up to three weeks. On the other hand, chronic bronchitis is a type of chronic obstructive pulmonary disease (COPD) which is a long-term, serious condition leading to production of cough with thick mucus and lasts for up to three months. Cigarette smoking, gastric influx, air pollution, allergy, and high exposure to irritants such as dust, chemicals, and fumes are the major risk factors associated with the development of bronchitis and chronic obstructive pulmonary disease (COPD).

Read Report Overview: https://www.transparencymarketresearch.com/bronchitis-market.html

Increase in morbidity and mortality associated with chronic bronchitis across the globe is a major factor driving the global bronchitis market. According to the Centers for Disease Control and Prevention (CDC), 8.6 million adults were diagnosed with chronic bronchitis in the U.S. in 2017. Similarly, 0.2 deaths per 100,000 population were caused due to bronchitis in the country in 2017. Changing lifestyles, exposure to irritants, smoking, and increase in the geriatric patient population are the other major factors anticipated to boost the growth of the global market during the forecast period. Furthermore, strong pipeline and favorable government initiatives to create awareness about bronchitis among the people are expected to augment the market from 2018 to 2026. However, patent expiry and stringent regulatory scenario are likely to restrain the bronchitis market in the next few years.

The global bronchitis market can be segmented based on type, treatment, end-user, and region. In terms of type, the bronchitis market can be bifurcated into chronic and acute. Based on treatment, the global bronchitis market can be categorized into drugs and oxygen therapy. The drugs segment can be classified into ant-inflammatory drugs, antibiotics, mucolytics, and bronchodilators. In terms of end-user, the bronchitis market can be divided into hospitals, clinics, and ambulatory surgical centers. The ambulatory surgical centers segment is anticipated to grow at a rapid pace during the forecast period owing to large number of visits to office-based physicians for lower respiratory disorders.

Obtain the Report PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60486

The global bronchitis market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to account for dominant share of the global bronchitis market between 2018 and 2026. This is attributed to rise in prevalence of bronchitis and increase in the number of deaths associated with the disease in the U.S. The bronchitis market in Europe is anticipated to expand at a high CAGR during the forecast period owing to increase in the geriatric population suffering from chronic bronchitis. According to NHS, approximately 2 million people are affected by chronic bronchitis in the U.K.; majority being adults aged over 50. Adoption of western lifestyle, rise in the number of baby boomers suffering from respiratory disorders, and excessive cigarette smoking in emerging countries such as India and China are the major factors boosting the growth of the bronchitis market in Asia Pacific. Latin America and Middle East & Africa are expected to present significant opportunities in the bronchitis market during the forecast period.

Key players operating in the global bronchitis market are Pfizer, Inc., Novartis AG, GlaxoSmithKline, Dr. Reddy's Laboratories Ltd., Kaiser Permanente, Inc., Sanofi Aventis, Cathay Drug Company, Inc., Boehringer Ingelheim, and AstraZeneca, among others. These players focus on investment in R&D to develop novel drugs for the effective treatment of bronchitis in order to expand product portfolio and strengthen presence across the globe.

Opt for the Discount on the Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=60486

About Us:

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: https://www.transparencymarketresearch.com